194 related articles for article (PubMed ID: 26348533)
1. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.
Borghardt JM; Weber B; Staab A; Kunz C; Formella S; Kloft C
Br J Clin Pharmacol; 2016 Mar; 81(3):538-52. PubMed ID: 26348533
[TBL] [Abstract][Full Text] [Related]
2. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
Borghardt JM; Weber B; Staab A; Kunz C; Kloft C
Br J Clin Pharmacol; 2016 Sep; 82(3):739-53. PubMed ID: 27145733
[TBL] [Abstract][Full Text] [Related]
3. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.
O'Byrne PM; D'Urzo T; Beck E; Fležar M; Gahlemann M; Hart L; Blahova Z; Toorawa R; Beeh KM
Respir Res; 2015 Aug; 16(1):97. PubMed ID: 26283085
[TBL] [Abstract][Full Text] [Related]
7. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
9. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
10. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
[TBL] [Abstract][Full Text] [Related]
11. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
13. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease.
Siederer S; Allen A; Yang S
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):743-758. PubMed ID: 26474864
[TBL] [Abstract][Full Text] [Related]
15. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
McGarvey L; Niewoehner D; Magder S; Sachs P; Tetzlaff K; Hamilton A; Korducki L; Bothner U; Vogelmeier C; Koch A; Ferguson GT
COPD; 2015; 12(5):484-93. PubMed ID: 25692310
[TBL] [Abstract][Full Text] [Related]
16. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
Kunz C; Luedtke D; Unseld A; Hamilton A; Halabi A; Wein M; Formella S
Int J Chron Obstruct Pulmon Dis; 2016; 11():585-95. PubMed ID: 27051282
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
[No Abstract] [Full Text] [Related]
20. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
